8-methoxy-4-(4-methoxy-benzylamino)-quinoline-3-carboxylic acid ethyl ester | 220844-62-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 8-methoxy-4-(4-methoxy-benzylamino)-quinoline-3-carboxylic acid ethyl ester
• 英文别名: 4-(4-Methoxybenzyl)amino-8-methoxyquinoline-3-carboxylic acid ethyl ester；ethyl 8-methoxy-4-[(4-methoxyphenyl)methylamino]quinoline-3-carboxylate
• CAS: 220844-62-2
• 化学式: C₂₁H₂₂N₂O₄
• 分子量: 366.417
• InChiKey: LPYPEYCCBQTKPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  69.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-氯-8-甲氧基喹啉-3-甲酸乙酯 、 4-甲氧基苄胺 以to afford 8-methoxy-4-(4-methoxy-benzylamino)-quinoline-3-carboxylic acid ethyl ester (290 mg)的产率得到8-methoxy-4-(4-methoxy-benzylamino)-quinoline-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors

  摘要：

  本发明涉及公式（I）所定义的化合物、制药组合物及其在治疗由TNF-α或PDE4介导的疾病或障碍，包括但不限于类风湿性关节炎的使用方法。

  公开号：

  US09393245B2

文献信息

• SWEET FLAVOR MODIFIER
  申请人：TACHDJIAN Catherine

  公开号：US20110245353A1

  公开（公告）日：2011-10-06

  The present invention includes compounds having structural formula (I), or pharmaceutically acceptable salts, solvate, and/or ester thereof. These compounds are useful as sweet flavor modifiers. The present invention also includes compositions comprising the present compounds and methods of enhancing the sweet taste of ingestible compositions. Furthermore, the present invention provides methods for preparing the compounds.

  本发明包括具有结构式(I)的化合物，或其药用可接受的盐、溶剂合物和/或酯。这些化合物可用作甜味调节剂。本发明还包括包含本发明的化合物的组合物以及增强可食用组合物甜味的方法。此外，本发明提供了制备这些化合物的方法。
• [EN] TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-a SYNTHESIS AND AS PDE4 INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE LA SYNTHÈSE DE TNF-? ET EN TANT QU'INHIBITEURS DE PDE4
  申请人：HIGH POINT PHARMACEUTICALS LLC

  公开号：WO2009094528A1

  公开（公告）日：2009-07-30

  The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-alpha or by PDE4, including but not limited to rheumatoid arthritis.

  本发明涉及化合物的化学式（I），如本文所定义，药物组合物以及在治疗由TNF-alpha或PDE4介导的疾病或疾病中的使用方法，包括但不限于类风湿关节炎。
• Tricyclic Compounds As Modulators of TNF-alpha Synthesis
  申请人：Mjalli Adnan M. M.

  公开号：US20100190808A1

  公开（公告）日：2010-07-29

  The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-alpha or by PDE4, including but not limited to rheumatoid arthritis.

  本发明涉及公式(I)所定义的化合物、药物组合物以及在治疗由TNF-alpha或PDE4介导的疾病或疾病中使用的方法，包括但不限于类风湿关节炎。
• Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors
  申请人：Mjalli Adnan M.M.

  公开号：US20110160234A1

  公开（公告）日：2011-06-30

  The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4, including but not limited to rheumatoid arthritis.

  本发明涉及化学式（I）所定义的化合物，制药组合物以及在治疗由TNF-α或PDE4介导的疾病或疾病中使用的方法，包括但不限于类风湿性关节炎。
• Tricyclic compounds as modulators of TNF-α synthesis
  申请人：High Point Pharmaceuticals, LLC

  公开号：US07964608B2

  公开（公告）日：2011-06-21

  The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-alpha or by PDE4, including but not limited to rheumatoid arthritis.

  本发明涉及式（I）所定义的化合物、制药组合物以及在治疗由TNF-alpha或PDE4介导的疾病或疾病中使用的方法，包括但不限于类风湿性关节炎。